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ABSTRACT
Industry-sponsored clinical research of investigational drugs (also called clinical
development) has traditionally been carried out in relatively developed countries in the North
American, Western European, and Pacific regions. However, lately it has been widely
reported that clinical trials starting now are becoming increasingly diffused globally, with
significant growth of activity in so-called emerging economies in Eastern Europe, Latin
America, and Southeast Asia.
This change in location of clinical development activities has numerous implications for
patients, health care providers, pharmaceutical companies, regulatory agencies and
governments around the globe. Even though there is much debate about the topic, a public
systematic quantitative assessment of the current status of the globalization of clinical drug
development phenomenon is lacking. The objective of this thesis research is to provide such
objective quantification while addressing some issues that are currently in active discussion.
This thesis documents that the participation of emerging countries is still relatively small
(13%) and they most commonly participate in very large (involving more than five countries)
phase lib or III trials. Albeit perceived as small, this participation is growing at a rapid pace
(23% average annual growth rate) and the number of clinical sites of global clinical trials
located in all emerging countries (11,038) is comparable with the sum of Germany, France,
U.K., and Italy (11,061). Eastern European and Latin American countries have the greatest
participation in clinical trials among emerging countries, but Southeast Asia is the region that
is experiencing fastest growth. Meanwhile, Western Europe has experienced negative
average annual growth of -8%, and North America has seemingly been stable.
This thesis discusses findings and key drivers behind the globalization process. I also
consider the argument that the sustainability of this model will depend on stringent
protection of patients in these emerging countries and continued development of these
nations, with eventual creation of an attractive market for pharmaceutical products. The
extension of this process of globalization of clinical trials, if coupled with substantial
improvements in health care delivery and research capacity in these emerging economies,
has the potential of revolutionizing medical product development within the next two
decades.
Thesis Co- Supervisor: Ernst Berndt, Ph.D.
Title: Louis B. Seley Professor of Applied Economics, MIT Sloan School of Management.
Thesis Co-Supervisor: Anthony Sinskey, Sc.D.
Title: MIT Professor of Biology & Harvard-MIT Professor of Health Sciences & Technology.
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II - Background
Clinical Trials of New Drugs
The development of a new drug therapy for a poorly treated medical condition
oftentimes brings hope and excitement to patients and their health care providers.
But before a novel medicine can be widely used in patients, clinical trials are
necessary. In these scientific studies the effects of the use of a new investigational
drug is examined in a tightly controlled setting and in a limited number of carefully
selected patients. These patients typically constitute a representative sample of the
patient population to be ultimately treated [1-3].
Clinical trials are initially carried out to determine the primary toxicity of the
novel intervention (also called phase I study), then to determine the optimal way to
administer the new drug (phase II) and ultimately to establish the safety and efficacy
of the optimized treatment (phase IlIl). Subsequent (post-approval or phase IV)
clinical studies are also carried out to study the effects and long-term safety of the
drug in special populations [2, 4, 5]. The vital importance of all these types of clinical
trials comes from the fact that even the best available biomedical science cannot
fully anticipate the way that patients will respond to a new form of treatment. This
insufficient ability of predicting the effects and/or toxicity of a new drug before the
first use in humans is not expected to be fully overcome in the foreseeable future [6-
9].
The investigational human use of newly developed drugs sponsored by
biomedical enterprises is often called clinical development. This process is regulated
in the United States by the Food and Drug Administration (U.S. FDA), and similar
systems of regulation are in effect in most countries [1, 2]. These regulatory
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agencies rely on statistical evaluation of the data generated in clinical development
programs for each new drug to decide whether it should be made available for
commercialization [3]. This type of clinical research that is designed to satisfy
regulatory requirements before approval for commercialization is usually sponsored
by pharmaceutical or biotechnology companies, which will ultimately sell the drug in
the marketplace.
Globalization of Clinical Development of Investigational Drugs
Industry-sponsored clinical research has traditionally been carried out in
relatively wealthy locations like the United States, Canada, Western Europe, Japan
and Australia. It has been reported that the size and the number of clinical trials
performed in these countries has been steadily increasing over the last decades [10,
11]. It has also been suggested that clinical trials are increasingly diffused globally,
with significant growth of activity in so-called emerging economies' like: Russia,
India, Poland, Brazil, China, South Africa, Argentina, Hungary, Mexico, and Czech
Republic. This growth has been particularly pronounced in the last 15 years, and it is
widely expected that it will be intensified in the upcoming decade [12-35].
It has been suggested that the main initial driver for the increased
participation of the these emerging countries in clinical drug development has been
the need to accommodate the overall increase in the demand for clinical research
[12, 14, 16-18, 20, 25-28, 31-33]. Over the last twenty years, the number of patients
The term emerging or developing will be used from now on to designate countries listed as "emerging markets" by the
publication The Economist@ on March 25th 2006 (China, India, Indonesia, Malaysia, Pakistan, Philippines, Singapore,
South Korea, Taiwan, Thailand, Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela, Egypt, Israel, Saudi
Arabia, South Africa, Czech Republic, Hungary, Poland, Russia, and Turkey), plus a number of countries that were NOT
in the list of high income countries tracked by The Economist! (Romania, Ukraine, Bulgaria, Puerto Rico, Slovakia, Ireland,
Croatia, New Zealand, Estonia, Greece, Portugal, and Lithuania). Even though some of these countries have relatively high
GDP, they can be seen as emerging from the clinical drug development perspective.
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enrolled in clinical trials of new medical interventions has risen dramatically, with
clinical studies enrolling several or even many thousands of subjects becoming
relatively common [4, 10, 11, 14, 24, 26, 31, 36, 37]. Some of the factors implicated
in this increase in number of subjects are the more complex nature of the diseases
being targeted by newer therapies, increasingly common necessity of comparing the
new drug with another one already in the market, and the increasing demands from
regulatory agencies [10, 11, 16]. Regardless of the cause, the greater need for
clinical data has gradually changed the nature and scope of these trials. From
relatively small clinical research projects performed within academic centers of
wealthy nations, clinical trials have morphed into sophisticated multi-national
operations [4, 11, 13, 14, 16-18, 21, 22, 24-28, 30-33, 35, 36, 38-44].
It has been suggested that the need for larger and more complex trials has
resulted in an increase in the expenditure in the clinical stage of drug development
by almost 200% in the last 15 years [10, 11, 45], bringing the estimated cost to
develop the first marketed tablet or capsule to values ranging from 400 million to 1.6
billion US$ [10]. The association of larger trials with increased clinical development
expenses comes primarily from the added administrative cost (more clinical sites to
be managed and patients to be treated) and opportunity cost (longer time-to-market
plus loss of patent-protected product lifetime).
There are also other increasingly important factors that should be included in
this equation. The first is the fact that the cost per research participant has gone up.
In the United States, this rise in cost is mostly due to increase in the expenses
devoted to staffing the clinical sites, which takes up the greatest proportion of the
calculated cost per subject [31, 46]. The second important factor is the substantial
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increase during the past decade in the absolute number of drugs that are getting to
the clinical development stage [11]. This phenomenon creates a situation where a
substantial number of eligible patients are already enrolled in trials, especially in
oncology studies performed within large academic medical centers in the U.S. The
competition for research subjects makes recruitment efforts even more difficult and
costly [1, 14, 31, 37, 46-48].
The increased cost of clinical development and the competition for subjects
have led developers of medical products to search for non-traditional locations
where they can: 1) perform clinical research having quality and patient protection
standards that are acceptable to the regulatory bodies (especially the U.S. FDA); 2)
pay less to appropriately staff a clinical site; and 3) recruit a large number of patients
in a timely manner [4, 11, 13, 16, 18, 21, 25-27, 42, 43, 46, 49].
Even though, from an industry perspective, the initial attractiveness of global
development proposition (allocation of some clinical trials operations outside
traditional countries) has been centered on the points cited above, there have also
been other important factors spurring this globalization phenomenon. These factors
include the ease of communication, enhanced training of international scientists and
health care administrators, the establishment of contract research organizations
(CROs) focused on global clinical development operations, the fast pace of growth
of market size, research capacity and regulatory demands in emerging economies,
and the harmonization of guidelines for clinical research.
The substantial improvement in the means for international communication
observed over the last fifteen years has enabled the globalization of clinical
development. Groundbreaking innovations in telecommunications systems, the
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development of the internet, relative ease of travel, and the establishment of English
as the universal language in the medical scientific community have significantly
facilitated communications within the medical scientific world [12, 31, 33].
Furthermore, numerous medical doctors, scientists and health care
administrators with cultural and/or professional ties to the emerging economies
obtained training in the United States or Europe and have decided to apply it in the
international arena. Even the professionals that did not formally obtain training in
academic centers in wealthy nations increasingly have had access to information
needed to run international clinical trials through training in local professional
schools, multinational institutions, or internet-based educational services. These
international professionals oftentimes develop the initiative to take an active role in
the creation of new medical interventions, because they have now a sustainable and
rewarding way of doing it [11, 19, 25, 26, 30, 33, 41, 46, 49, 50].
These international scientists and health care professionals have either
created local/regional research organizations or have been assimilated by
multinational companies, especially CROs, which have been establishing
increasingly complex ties among scientific institutions of different countries. During
the last fifteen years, these CROs have been gradually capturing a substantial
proportion of the global clinical trial operations from medical product developers, and
the valuable contacts that they have with talented professionals within the emerging
economies has been widely employed as a convincing selling point [25, 26].
Taking a broader perspective, the increasing participation of emerging
economies in biomedical R&D is likely part of a relatively new trend in high-tech
product development. Drawing a parallel with the software industry, the first kind of
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activities in product development that were outsourced to developing countries like
India were data-intensive, as opposed to knowledge-intensive, research operations
[50, 51]. Such activities in India tended to be mostly related to testing and to code
writing that was not core to the technology. This initial type of R&D partnerships has
been considered cost-effective because of the ease of international communication
and the presence of local well-trained computer engineers [52]. In the biomedical
industry, the most data-intensive part of the medical product development process is
the performance of late-stage clinical trials, and also in the large-scale preclinical
medicinal chemistry and preclinical testing of experimental animals [18]. Given the
precedent set by the software industry, it is not surprising that these data-intensive
activities have been the first ones to be performed in the developing world [50].
Countries that are now seen as emerging economies will become important
markets for medical products relatively soon, and this fact may well gradually
change the rationale behind international R&D partnerships [48, 52, 53]. Using
another example from the software industry, one of the most important R&D
operations of Microsoft® is now located in Beijing, China. The mission of this R&D
outpost is not only to create global products from scratch, but also to develop ideas
targeted at the - to be huge - Chinese market [51]. In the biomedical field we have
the example of the largest Indian pharmaceutical companies, which have made the
strategic decision to become fully integrated biomedical innovators, competing in the
global market and also creating products tailored to their local population [54].
Likewise, large pharmaceutical companies are increasingly establishing more
knowledge-intensive product development operations in locations like China, India,
Eastern Europe and Latin America [11, 14, 19, 25, 26, 49, 55-59]. These
14
multinational pharmaceutical companies are also looking forward, with one eye on
the global market and the other one on local ones [14, 48, 53].
Governments of developing countries are also taking the opportunity to
become involved in medical product development as a strategic matter. One
example of such a strategic view is the initiative by the Brazilian government, in
partnership with private entities, to build clinical research centers around the country,
essentially to host international and local trials [60]. Likewise, Chinese officials are
working hard to bring good clinical practice standards to their hospitals, so that they
are more attractive to international developers [20, 24]. The Indian government has
just implemented a drastic policy change as it relates to intellectual property
protection, in which they are going to respect international patents [54, 61]. That is
going to damage their generic pharmaceutical industry, but the fact is that some of
the generic manufacturers were the main companies that lobbied for this move. The
main reason why they did so was to ensure that the intellectual property associated
with the drugs that they begin to create, as they became innovators, is protected.
The second, and also important, reason for their move was that the same
companies also have important clinical trial operations that serve international
developers. Thus, they want to attract international trials by making sure that
intellectual property related to drugs and devices are protected when they are tested
in India [54].
All these recent news represent the increasingly forward-looking global view
shared by governments and biomedical entrepreneurs of some developing
countries. These officials are interested in developing stronger international trade
relations and they are fully aware that there is more wealth to be generated in
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information-based economic activities. In the biomedical field, these countries
anticipate the creation of new types of employment opportunities for health care
workers, who are obtaining highly valuable and specialized training. Physician and
support personnel that are trained to perform according to international health care
standards during clinical research activities can be expected to become more
capable and judicious professionals outside the clinical research scenario, when
treating regular patients [2, 3, 16, 22, 46, 59, 62-64]. The other potential benefit is
that research and medical care infrastructure can initially be built mostly by using
foreign direct investments from multinational corporations, possibly creating a
capacity that can ultimately serve to foster development of an indigenous biomedical
industry.
It should also be noted that government officials of progressively more
sophisticated emerging economies are beginning to realize that the scientific
evaluation of new investigational drugs in the local population is important. They are
becoming increasingly aware that the relatively blind acceptance of clinical
information obtained solely from foreign patients (traditionally from Caucasian
populations of wealthy nations) that we have today may not be appropriate as local
cultural and ethnic factors can substantially affect the patient's response to a new
treatment.
The maturation of the guidelines for international clinical research can also be
considered as a very important factor in the globalization of clinical drug
development. Several codes of conduct have been created in response to apparent
unethical practices in clinical research in wealth nations over the last century. The
Nuremberg Code (with all its revisions), the Belmont Report, and the NIH's
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guidelines for clinical research are important in this context as they represent the
learning that has occurred from several most unfortunate experiences [2, 12, 22, 23,
29, 34, 37, 40, 41, 44, 59, 65-83]. Two more recent reports build upon these and
consider especially the conduct of clinical trials in developing countries. The first one
is from the U.S. National Bioethics Advisory Commission [28], which defined ways to
protect vulnerable populations of developing countries from exploitation. The second
report is divided up in a series, as are the results of the International Conference(s)
on Harmonization (ICH) of Technical Requirements for Registration of
Pharmaceuticals for human use. This series of reports defines how clinical data
should be obtained and presented, how informed consent should be obtained, and
how institutional review boards should operate [5, 39, 67, 84-87].
These above-mentioned guidelines provide protocols on accepted ways to
perform trials in developing countries, offering an equivalent level of patient
protection that is afforded in developed countries. The existence of the guidelines,
however, does not guarantee that subjects of emerging nations will be protected.
The strength of the local legal system and quality of training of local investigators
and support personnel will ultimately determine the level of compliance with
international ethical standards. Based on the scale of the public reaction to recent
clinical trials that were perceived not to be complying ICH's Good Clinical Practices
standards [1, 12, 13, 27-29, 32, 36, 40-42, 47, 55, 56, 61, 69, 73, 76, 78-83, 88, 89],
it is increasingly clear that the long-term sustainability of clinical trials operations of a
given country will depend critically on its ability to protect human subjects.
In summary, many factors are playing important roles in the globalization of
medical product development, and it can be concluded that this is an inevitable and
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most likely desirable trend. Even though the main initial driver for the globalization of
medical product development was the need of product developers to obtain more
access to research subjects and cut costs in data-intensive R&D operations, several
other wide-ranging and important factors have been involved in the process. As I
have discussed, the globalization of clinical trials appears to represent the initial
phase of a far-reaching trend towards internationalization of product development,
with a gradual assimilation of a global view into private enterprises and
governments. It can safely be predicted that these international R&D operations will
gradually become more knowledge-intensive and sophisticated within the next ten to
fifteen years. It is also expected that within the upcoming twenty to thirty years some
of the emerging developing countries that are currently hosting data-intensive R&D
operations will be seen mostly as important markets for pharmaceutical products
[14, 48, 51-53].
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111 - Characterization of Global Clinical Trials
The 2001 report of the United States Office of Inspector General (OIG) [41]
entitled "The Globalization of Clinical Trials - A Growing Challenge in Protecting
Human Subjects" was likely the first systematic quantification of the increased
submission of data generated by investigators outside the FDA's jurisdiction (U.S.)
published in the Medline-indexed literature. The authors reported that between 1980
and 1999 the number of clinical investigators conducting drug research under FDA's
Investigational New Drug (IND) applications outside the U.S. increased 109-fold,
from 41 to 4,458.
The globalization of clinical drug development heralded in the OIG report [41]
has been referred to as one of the most important recent transformations in the
biomedical industry [14, 26, 31, 46, 53, 54], but the globalization term in this context
has varying meanings for different people. As mentioned earlier, some focus on the
relatively low cost of running data-intensive and large-scale product development
operations in emerging economies [12, 13, 16, 24-26, 31, 36, 41, 90]. Others point to
the leveling of the playing field phenomenon [91], in which high-quality research
centers, located in countries of any size or socioeconomic status, can now
participate in the global product development process because of today's ease of
communication and harmonization of Good Clinical Practice (GCP) guidelines [4, 14,
31, 32, 53]. There is also the view that the increasing bargaining power (larger
market) and sophistication (better technical education) of regulatory agencies of
certain emerging economies are gradually forcing drug developers to increase the
number and quality of the clinical development operations in these countries [14, 16,
46, 52, 53, 90]. Regardless of one's position on any of these interrelated issues, it
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seems quite relevant and important to understand the evolution of the participation
of emerging nations in drug development operations over the last few years.
Such evolution of the globalization process was addressed in the 2001 OIG
report, which stated that the mid 1990's was the point in time when the geographic
allocation of clinical trials began to change substantially (Figure 1). The growth in the
number of these foreign clinical investigators participating in industry-sponsored
international trials has been particularly dramatic in the last five years covered by the
OIG study (1995-1999). A group of countries (Argentina, Brazil, Hungary, Mexico,
Poland, Russia, and Thailand) were singled out as ones showing the greatest
growth in their participation in clinical drug development through the 1990's.
Although interesting, the analysis presented in the report does not put the
participation of each of these countries in a broader context. In other words, it is not
clear how the number and growth of clinical investigators in each of these depicted
countries compares to those of other more traditional countries, such as the U.S.,
Canada, U.K., France or Germany. Furthermore, the basic characteristics
(therapeutic categories, phase, total number of countries participating, number of
patients, and sponsor) of the trials with clinical sites located in these emerging
countries have not been described and analyzed.
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Figure 1 (Source: 2001 Office of Inspector General Report)
Another important aspect not fully addressed in the OIG report is the
magnitude of the participation (number of active clinical research sites) of very poor
countries, especially in sub-Saharan Africa. This information is relevant as the
performance of industry-sponsored trials in such countries is controversial. The main
contention is that, in many cases, these countries do not have the health care
infrastructure that would allow the performance of clinical trials following GCP
guidelines (as defined by the International Conference on Harmonization (ICH) [5,
84]. Several reports have been published describing problems in clinical research
performed in some of these countries [28, 29, 66, 78, 81], and it is not known
whether there are still substantial clinical development activities in these locations.
A more precise quantification of the number of clinical research sites located
in emerging countries is also lacking. These countries frequently have at the same
time characteristics of both wealthy and poor nations, and inequalities in health care
access and relatively underdeveloped patient protection systems are still serious
problems. The socioeconomic status of these emerging countries might create
situations where key tenets of clinical research, like culturally-sensitive ethical review
of research protocols and informed consent are compromised [3, 16, 18].
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Table 2
Clinical Investigators Working Under IND
Reguldations in Snieced Countries.
Fiscal Year 1991 to 1999
C011111 M-3 M61 W4*
Au.. a 122 271
vivid 16 2 137
· 36 101
lM1110 29 48 167
Puawe 4 I= IN
Runk a 6 170
TINM 1 2 24
Somue: COG anaris of FDA dzm
For that matter, one could look in the composition of countries participating in
any given trial to determine whether trials performed most often in these emerging
nations only have sites in countries of similar (lower) socioeconomic status. This
finding could be seen as an indicator that these trials have research protocols that
would not be acceptable in places like the United States or Western Europe2 .
It might be the case that an alternative scenario is actually becoming
dominant over the last few years: new trials have an equivalent participation of
traditional and emerging countries, with a mix that can be correlated with their
market potential and current clinical research capacity. Such finding could be seen
as an indicator that new drugs are tested for efficacy and safety (in phase lb/Ill
trials) at the same time in all potential markets - traditional and emerging - so that
concomitant global registration can be executed quickly and efficiently, using both
international and local data [92].
Before the creation of the International Conference on Harmonization (ICH)
guidelines in the early 1990's, major pharmaceutical companies conducted relatively
independent clinical development programs in the U.S., large Western European
countries and Japan. Data from each of these programs was then used for appraisal
and eventual approval for commercialization by each of the respective regulatory
agencies. Only after such approval in wealthy nations, relatively small post-
marketing local registration studies (phase IV type) would be conducted in some of
the largest developing countries in order to obtain approval for selling such drugs in
these relatively small markets. Sometimes, these developing nations simply
2 It might also be the case that emerging nations are hosting trials of therapies for diseases that are
uncommon in wealthy countries, as is the case for certain infectious diseases like rotavirus
enterocolitis and also for rare types of cancers like nasopharyngeal carcinoma (highest prevalence in
Southeast Asia)
22
accepted the decision made by the FDA without requiring the companies to perform
further local studies [92].
Within the possibly up-and-coming global registration paradigm mentioned
above, two separate and parallel processes appear to be shaping strategic decisions
regarding geographical allocation of clinical sites today. The first is that the ICH
guidelines and the increased cooperation among the FDA, European Agency for the
Evaluation of Medicinal Products (EMEA), and other regulatory agencies across the
globe has enabled the implementation of global clinical development programs that
make use of numerous sites in each of the current major markets for pharmaceutical
products (North America, Western Europe; and Japan) [4]. The second is that
pharmaceutical developers most likely began to take notice of predictions that some
of the emerging nations will have sizable markets when their new drugs go through
their usual twelve year development cycle [10]. The expected result is the creation of
large pre-approval confirmatory (phase lb/Ill) trials involving a combination of
wealthy and emerging nations, which would be designed to enable fast concomitant
registration in a global scale once they are completed. But again, there are no
empirical foundations to support or disprove this perception.
Likewise, the pace of evolution of the globalization of clinical drug
development is not well-understood and without such information it becomes difficult
to forecast near to mid term trends. In fact, in other to generate such predictions one
ideally needs to identify the growth rate of participation in global clinical trials of all
countries heavily involved in global clinical trials, and not just a few ones. The
unsubstantiated conjecture that clinical trials in wealthy nations are being replaced
by trials in emerging economies [14, 90] can also be addressed with such type of
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empirical analysis.
The analysis of annual growth rates of countries involved in clinical drug
development might also enable the assessment of the impact of country-specific
public policies, implementation of local regulations governing clinical research and
related intellectual property, building of health care infrastructure, training of medical
and support personnel and major investments by the private sector. Of special
interest is the growth rate of participation in global clinical studies of countries like
India and China, which is not known, but nonetheless has been the subject of much
public and scientific debate over the last 5-10 years [11, 16, 18, 21, 22, 24, 27, 31,
35, 36, 42, 53, 54, 57, 61, 90].
In summary, global clinical drug development is a rapidly evolving field and
the evolution of this model of drug development will likely have great impact on the
behavior of companies, regulatory agencies, hospitals, research enterprises, health
care professionals, and ultimately patients. As pointed out in the 2001 OIG report,
the globalization of clinical trials raises numerous critical issues, especially in terms
of patient protection. At the same time, the value of global clinical drug development
to patients and society as a whole is clear.
To date, most of the discussions on globalization of clinical trials to date have
been based on, sometimes outdated, testimonials from professionals in the field.
These do not necessarily present a broad and objective perspective on how the
phenomenon presents itself today (2006). What is needed is an impartial and
comprehensive quantitative mapping of today's industry-sponsored global clinical
trials that can be used to address many of the pressing issues described above.
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IV - Objectives and Hypotheses
One goal of this thesis research is to generate a quantitative assessment of
the evolution of industry-sponsored global clinical trials of investigational drugs
(hereafter, GCTs) that took place after the publication of the OIG report in 2001.
In order to provide such a quantitative assessment, the countries most heavily
involved in global clinical development (the top 50) were divided according to two
different classification schemes, the first one related to global clinical trial
participation (ranking of total number of clinical sites and level of engagement in
global economy) and the second one related to geopolitical region.
In the first classification scheme the groups were called: tier 1 traditional; tier
I emerging; and tier 2 emerging (table 1). I have used the arbitrary cut-off point of
400 clinical sites to divide the countries into tier 1 and tier 2. The tier group was
further subdivided in tier traditional and tier I emerging, with the emerging
countries being the ones defined as "emerging markets" and the traditional ones
referring to those tracked as established markets by the magazine The Economist®
on April 25th of 20063
Most of tier 2 countries were in the "emerging markets" list of The Economist®
as well, while a few were neither the emerging nor in the traditional markets
segment. For the sake of simplicity, all countries of tier 2 will be referred to as
emerging as well, based on the collective behavior of this somewhat heterogeneous
group in relation to participation in clinical development operations 4.
3 This classification is one that is published weekly on the back pages of the printed publication
version, and not the e-readiness ranking published yearly by The Economist's Intelligence Unit® .
4 No classification regarding complex entities like countries is perfect. I chose to rely on the somewhat
incomplete classification used by The Economist® because it seems to be the one that best captures
the positioning of countries related to their economic performance over a period of time, especially as
it refers to market size growth potential and level of engagement in the global economy.
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In the second classification scheme, the countries were subdivided in the
following geopolitical regions (table 1).
GROUP Countries
Tier I Traditional (17) U.S., Canada, Germany, France. U.K., Italy, Spain, Australia. Japan, Belgium,
......_____ _ Netherlands, Sweden, Denmark. Norway, Austria, Finland, and Switzerland
Tier Emerging (10) Poland, Russia, South Africa, Brazil, Czech Republic, Argentina, Mexico, Hungary, India,
and China/Hong Kong
South Korea, Greece. Israel, Taiwan, Romania, Ukraine, Portugal, Bulgaria, Puerto Rico,
Tier 2 Emerging (23) Slovakia. Chile, Turkey, Ireland. Thailand, Philippines. Croatia, Malaysia, New Zealand,
Singapore. Estonia, Peru. Lithuania, and Colombia
REGION Countries 
North America (3, . U.S.. Canada, and Puerto Rico (U.S. Dependent Area)
Western Europe (15) Germany. France, U.K., Italy, Spain, Belgium. Netherlands. Sweden, Denmark, Norway,
Austria, Finland, Switzerland. Portugal, and Ireland
Eastern Europe (13 Poland, Russia, Czech Republic, Hungary, Greece, Romania, Ukraine, Bulgaria.Eastern Europe (13)
.......... Slovakia, Turkey, Estonia, and Lithuania
Pacific (3) . Australia, Japan, and New Zealand __
Latin America 6) Brazil, Argentina, Mexico. Chile, Peru, and Colombia
Southeast Asia (8) India. China/Hong Kong, South Korea, Taiwan, Thailand, Philippines, Malaysia. and
Southeast____Asia____) Singapore
Africa (1) South Africa _
Middle East (1. Israel
Table 1
Classification schemes of countries tracked in the study. The first classifications is related to clinical trial participation (ranking
of total number of clinical sites and level of engagement in global economy) and the second one is related to geopolitical region
in which the country is situated.
In this context I will address the following hypotheses:
1) The top 50 countries that are most actively taking part in global clinical trials
of investigational drugs either have high income per capita (more than
US$10,0005 in 2005) or are "emerging markets" tracked by The Economist® .
2) The participation share of emerging countries in global clinical drug
development has continued to increase over the last four years, while the
participation share of traditional countries has been decreasing.
3) Emerging countries have a greater level of participation in large multinational
studies (with sites in more than five countries) than do traditional countries.
4) Emerging countries have a level of participation in the confirmatory phases
(phases 1/111) of clinical development at a rate that is comparable to that of
traditional countries.
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5 CIA World FactBook.
V - Methods
Source of Information
I obtained information on global clinical trials of investigational drugs from the
Clinicaltrials.gov website up through March 1st 2006. This public web-based registry
has become increasingly comprehensive in recent months as a result of initiatives
enacted by the U.S. federal government and the editorial boards of major medical
journals.
Clinicaltrials.gov contains information of clinical trials performed under a U.S.
FDA investigational new drug (IND) application. Sponsors plan to ultimately use
information obtained in these registered trials to obtain regulatory approval for
marketing of a new drug or indication. The U.S. legislation requires registration only
of trials for medical interventions designed to treat serious or life-threatening
diseases. The guidelines for such submissions were developed as a mandate
contained in the 1997 U.S. FDA modernization Act [93-96].
More recently (September 2004), members of the International Committee of
Medical Journal Editors (ICMJE) published a joint editorial aimed at promoting
registration of all clinical trials in the clinicaltrials.gov database, irrespective of the
seriousness of the disease being studied, type of research protocol or source of
funding [97]. This committee represents several of the most important publication
outlets for clinical trials (e.g., New England Journal of Medicine, Lancet, Journal of
the American Medical Association, among others), and the consortium announced
that results from trials will only be considered for publication if they have been
registered at clinicaltrials.gov before the enrollment of the first patient. This policy
applies to trials that began recruiting on or after July 1, 2005. As many ongoing trials
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were not registered at inception, the journals will consider for publication ongoing
trials that were registered before September 13, 2005.
Database of Global Clinical Trials
General Description
A database containing information on 1,894 trials, and corresponding 59,487
clinical sites, was created as a Microsoft Excel® file. Detailed descriptions of trials
that fitted the inclusion and exclusion criteria (listed below) were saved as Acrobat®
PDF files on March I s t 2006. The data contained in these files were analyzed over
the ensuing months without having to deal with the fact that the studied internet
registry is modified to some extent almost daily. Information captured from each
detailed trial description was manually entered into the Excel® spreadsheet.
The information retrieved from clinicaltrials.gov included: name of trial;
clinicaltrial.gov identifier number, number of patients to be enrolled (when available);
recruitment start date (when available - for currently recruiting trials); listings of
clinical trial site locations; condition being treated; and sponsor.
Before beginning to collect such data points, I first generated a list of the top
50 performing countries in clinical development (including the U.S.). This list was
created with the use of the "focused search" tool on clinicaltrials.gov. This interactive
tool provided the total number of trials registered at clinicaltrials.gov that each
country is participating, regardless of the magnitude of their contribution in terms of
number of clinical sites. The numbers of all countries for which data was available
were tabulated and the top 50 countries were then identified.
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After the identification of the top 50 countries, I went beyond the level of
analysis offered by the clinicaltrials.gov "focused search" interactive tool by counting
the number of sites that each country had in each trial. This data compilation was
driven by the assumption that there is a substantial difference between situations
where a country has one site in a global trial compared to another where it
participates with 100 sites. In both realistic scenarios the country would be listed in
the same way on clinicaltrials.gov. After the data points about each trial were
entered into the Excel® spreadsheet, it became quite straightforward to generate
quantitative assessments related to specific countries, or groups of countries, taking
part in global drug clinical development. It also became relatively simple to study
groups of trials that shared common characteristics such as: trial phase, total
number of countries participating in each trial, and recruitment start date.
Inclusion & Exclusion Criteria
I have collected information of "currently recruiting" and have excluded "not
yet recruiting" or "terminated" trials. I have also gathered data from "completed" trials
in the cases where the sponsor provided a date of start of recruitment.
As my ultimate goal is to characterize GCTs in this study, I have not collected
information on purely domestic trials (with clinical sites only within the U.S.).
According to the clinicaltrials.gov own analysis, about 30% of the trials fall into this
category. Likewise, I have excluded trials funded and/or run by academic or public
institutions from the analysis, because of the understanding that they are intrinsically
different from the industry-sponsored trials. I determined that a given trial was
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industry-sponsored when the sponsor name was listed in the field "Information
Provided by" on the clinicaltrials.gov website.
I also did not collect information on studies in which the clinical phase (1/11/111l
or IV) was not provided by the sponsor. From the provided description of trials that
fell in this category, it could be determined that in these trials the sponsors were not
testing or observing the effect of an industry-owned medical intervention. Most of the
industry-sponsored clinical studies of this kind had the objective of determining the
prevalence of a condition in a selected population that is not using the drug, making
them intrinsically different from the most common type of trial in which a company is
seeking information that will be ultimately used to make statements that are
specifically related to the effects of their drugs in humans.
Trials that did not have information on location of clinical sites or condition
treated were excluded as well. Trials that fell in either category were uncommon and
were considered of no use for the purposes of this study. I have also excluded trials
of medical devices that did not rely on a drug for its therapeutic effect as my focus in
this study is on pharmaceutical development.
A total of 50.2% of the trials that were identified as industry-sponsored by the
clinicaltrial.gov website on March 1st 2006 were excluded according to the above-




The ranking of country participation in GCTs was based on the total number
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of clinical sites of all top 50 countries6 . Sites located outside the top 50 countries
were counted collectively and numbers were placed in a bin labeled "others". I have
also quantified the proportion of clinical sites that each country contributed to GCTs
by dividing the country's total number of sites by the total number of clinical sites
tracked in the current study, which was 59,487.
Growth Rates
The first step in the determination of growth rate was the separation of trials
according to date of start of recruitment (2002, 2003, 2004, and 2005). Separate
rankings were generated that corresponded to trials that were initiated in each given
year7. The second step was to determine the share of clinical trial participation of all
countries in each year. These shares were determined by dividing the number of
clinical sites of individual countries in each year by the sum of the clinical sites of all
countries in the same year8 .
The average annual growth rate of share participation for each country was
determined with the arc (arithmetic mean) formula9: arc = (St- St-1) / ((0.5*(St + St-1)).
6 Each clinical site in this context refers to a recruiting location for an individual clinical trial. Specific
identity of the medical center in which the site is located is usually not provided by the registry. Even
though it is possible that any given hospital or clinic might be recruiting patients for more than one
trial, sites were counted individually for each trial, and added up as separate entities.
7 I did not include information for trials starting during the years below 2002 and for the two first
months of 2006 because of an insufficient number of data points.
' It was assumed that most of the systematic increase in number of trials from 2002 to 2005 was due
to a higher reporting of more recent trials. For the purpose of the growth rate calculation, it was then
assumed that the overall number of sites in global trials was kept constant over the last four years,
and the only thing that changed was the reporting. This analytical strategy was used because an
overall annual growth rate over the last few years is not known precisely and any given figure can be
easily included in the mathematical model during the discussion of the results.
' This formula was chosen because it captures the year-to-year changes and also handles small
numbers of clinical sites that some countries present in a reasonable manner. St means numbers of
trials in a given year. St-1 means number of trials in the previous year.
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The weighted1 0 average annual growth rates for the groups of countries classified
according to global clinical development participation and geographic location were
also determined.
Participation in Very Large Clinical Trials
One way to measure the size and complexity of a given clinical trial is to
determine the number of countries that participate in the trial. In this study, clinical
trials were separated according to the number of countries participating in them. I
then determined the number of clinical sites that each country had in trials involving
more than five countries, which is my working definition of large multinational trials.
The proportion of sites that each country had in these large trials (as opposed to in
trials with four or less countries) was then established for each country. The
weighted average proportion of participation in these large trials was also
determined for the groups of countries classified according to global clinical
development participation and geographic location.
Participation in Confirmatory (Phase II and ) Clinical Trials
The clinical sites of all top 50 countries were also separated according to the
phase of the trial in which they were participating. The proportion of clinical sites that
each country had in confirmatory trials (phase 11/111), as opposed to post-marketing
(phase IV), trials was determined for each country. The weighted average proportion
of participation in these phase 11/111 trials was also determined for the countries
10 The weighing procedure to calculate the rate of a given group or region was performed by the
division of alb, where a is addition of the results of the multiplication of total number of clinical sites of
each country of a group or region with their perspective individual rates; and b is the sum of number
of clinical sites of all countries within a given group or region.
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Ranking Country of Sites % of Total Ave. Ann .R. % in Large Trials %/; in Phase IHIU
1 U.S. 23144 38.9%1 1.5% 26.8% 89.7%
2 Canada 3902 6.6% -9.5%52.3% 86.0%
3 Germany 3705 6.2%, -21.9% 71.4% 89.,%
4 France 3451 5.8% 1.7% 62.9% 81.5%.
5 UK 2011 3.4% -17.6% , 82.8% , 81.2%
6 Italy 1894 3.2% -26.1% 70.3% 79.5%
7 Spain 1851 3.1% 2.7% 84.4% 79.5%
8 Australia 1346 2.3% -0.2% 75.3% 87.3%
9 Japan 1302 2.2% 2.6% 0.1% 92.3%
10 Belium 1099 1.8% 4.2% 86.4% 89.6%
11 Netherlands 1075 1.8% 14.5% 73.8% 69.3%
12 Sweden 1048 1.8% -6.1% 76.3% 77.9%
13 Poland 1003 1.7% 13.6%Y 87.2% 92.0%
14 Russia 844 1.4% 27.6% 77.4% 84.8%
15 South Africa 729 1.2% -2.3% 89.8% 86.8%
16 Brazil 722 1.2% 0.9% 92.5% 88.5%
17 Denmark 687 1.2%; 11.9o 57.6% 63.5%
18 Czech Republic 634 1.1% 27.7% 90.4% 89.6%
19 Argentina 624 1.0% 272% 96.3% 91.2%
20 Norway 601 1.0% -13.0% 83.5% 83.0%
21 Mexico 585 1.0% 28.7% 88.7% 87.0%
22 Hungary 564 0.9% 36.3% 90.1% 91.0%
23 Austrna 465 0.8% .12.8% 64.9% 87.0%
24 Finland 463 0.8% 11.6% j 76.9% 85.9%
25 India 420 0.7% 40.1% 85.2% 86.7%,
26 Switzerland 405 0.7%. -17.5% 63.7% 81.9%
Others 403 0.7% 30.7%, 73.0% 80.8%
27 China (wiH. K 399 0.7% 61.9% ' 49.6% 79.3%
28 South Korea 322 0.5% 18.7%. 66.8% 82.3%
29 Greece 316 0.5%1 25.5%. 85.1% 72.5%
30 Israel 317 0.5% 12.4% 85.2% 92.4%
31 Taiwan 290 0.5% 12.8% 79.3% 83.6%
32 Romania 281 0.5% 32.0% 86.5% 90.7%
33 Ukrainrte 270 0.5% 29.7% 75.2% 95.6%
34 Portugal 251 0.4% 20.3% 91.6% 78.5%
35 Bulgaria 247 0.4% 62.0% 76.9% 97.2%
36 Puerto Rico 237 0.4% 8.2% 55.3% 77.6%
37 Slovakia 164 0.3% , 24.7% 99.4% 90.8%
38 Chile 141 0.2% 51.2% 95.0% 86.5%
39 Turkey 140 0.2% 16.9% 86.4% 63.6%
40 Ireland 137 0.2% -3.4% 93.4% 83,9%
41 Tlhailand 127 0.2% 37.4% 80.3% 74.8%
42 Philppines 126 0.2% 80.8% 92.9% 92.9%
43 Croatia 113 0.2% 37.6% 81.4% 85.0%
44 Malaysa 113 0.2% 42.1% 91.2% 87.6%
45 New Zealand 110 0.2% 27.9%. 86.4% 89.5%
46 Singapore 90 0.2% 23.2% 90.0% 85.2%
47 Eslonia 87 0.1% 12.8% 97.7% 87.4%
48 Perti 86 0.1% 89.8% 84.9% 89.5%
49 Lithuania 76 0.1% . 12.5% 90.8% 75.0%
50 Colombia 70 0.1% 1 61.9% . 91.4% 80.0%
Ranking !GROUP % of Total Ave. Ann. G.R. Ave. % in Large Trials Ave. % in Phase lUlII
1 Tier I Traditional (17) 81.4% -3.2% 47.4% 86.4%
2 Tier I Emerging (1 ) 11.0% 22.9% 86,0% 88.1%
3 rier 2 Emerging (23) 6.9% 25.6% 83.8% 83.7%
4 Others 0.7% 31.3% 73.0% 80.8%
Ranking REGION % of Total Ave. Ann. G.R. Ave. % in Large Trials Ave. % in Phase 111111
1 North Ameica (3) 45.9% 0.0% 30.7% 89.1%
2 Westem Europe (15) 32.2% -7.9% 73.86% 81.7%
3 Eastem Europe (13) 8.0% 26.3% 85.3% 87.8%
4 Pacific 3) 4.6% 2.2% 40.2% 89.8%
5 Latin Amernca (6) 3,7% 24.1% 92.4% 88.5%
6 Sottheast Asia (8) 3.2% 29.8% 81.1% 83.6%
7 Aftica(1) 1.2% ~1.9% 85.9% 86.8%.
B Middle East (1) 0.5% 8.2% 86.3% 92.4%
Table 2
Quantitative assessment of global clinical development operations of individual countries, groups of countries and geographic
regions. Rankings of clinical trials participation is represented by the number of clinical sites, with the tier traditional countries
labeled in brown (regular font), tier I emerging in green (bold italics), tier 2 emerging in yellow (bold), and "Others" is white
(bold). Average annual growth rate (2002 through 2005) of all countries and regions was established. Proportion of instances
where countries or regions participated in large (>than 5 countries) trials, or in confirmatory trials (phases 11/111, as opposed to
IV) are also depicted. Numbers of countries in each group or region are shown inside parenthesis. *China was classified as tier
1 emerging because its number of sites (399) was very close to the arbitrary cut-off of 400 sites that divided tiers I and 2.
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Rankings
The ranking of country participation (based on number of clinical sites)
suggests that the overwhelming majority of GCT clinical sites today is still located in
the tier traditional countries (81.4% of total - in light brown). Of the remainder
18.6%, the tier 1 emerging countries (in light green) accounted for 11% and the tier 2
emerging (yellow) accounted for 6.9%. If one includes in the computation of the
overall number clinical development activities globally the rough estimate of 25,949
sites1 1 that would correspond to "U.S. only" domestic trials excluded from the
database, it can be inferred that the participation of emerging countries amounts to
about 13%.
The number of clinical sites in the U.S. is at least six times greater than in any
other country, and this difference is probably even greater considering that the
clinical trials with sites only in the U.S. are not represented in this database of GCTs.
Canada is the prime destination for clinical sites outside the U.S., and it is closely
followed by Germany and France.
The emerging countries in Eastern Europe have more than double the
amount of sites in Latin America, but Eastern Europe involves a greater number of
countries (13 vs. 6). Southeast Asia has only two representatives at the bottom of
the tier group, and has fewer sites than Eastern Europe and Latin America, even
though it has a much larger population.
Some of the top performing tier 1 emerging countries - especially Poland,
Russia, South Africa, and Brazil - have a level of participation that is quite
comparable to that of some traditional countries. There is only one representative of
" If 59,487 amount to 70% of the trials, 25,494 would correspond to the other 30%.
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the Middle East (Israel) and of the African continent (South Africa) in the top 50
performing countries. The sites represented in the "others" bin amount to a small
proportion of GCTs (0.7%), especially considering that they refer to at least 20
countries. Most of the countries included this bin were in Europe, Latin America and
Asia. Latvia, Serbia & Montenegro, Luxemburg, Slovenia, Panama, Costa Rica,
Venezuela, Ecuador, Indonesia, Vietnam, Pakistan, Algeria, Morocco and Saudi
Arabia were the countries that had the most prominent participation in this group.
It can be concluded that hypothesis 1) is valid. The top 50 countries that are
most actively taking part in global clinical trials of investigational drugs either have
income per capita higher than US$ 10,000 (based on CIA World FactBook 2005) or
are emerging markets.
Growth Rates
As seen in the middle panel of table 2, the tier traditional countries had a
negative average annual growth rate of -3.2%, while the tier emerging countries
had a positive rate of 22.9% and the tier 2 emerging ones had a positive rate of
25.6%. The greatest proportion of the traditional countries (8 out of 17) posted an
average growth close to 0% (-10% to +10%) in relation to the overall annual rate of
increase in overall clinical trial activities, which is an unknown figure. Some of the
traditional countries had a rather pronounced (more than 10%) negative growth rate,
and these included Germany, U.K., Italy, Norway, Austria and Switzerland, while
others (Netherlands, Finland, and Denmark) had positive growth in excess of 10%.
The great majority (91% - 30 out of 33) of the emerging countries (30 of 33)
experienced a positive growth rate, with an average for the whole group running
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above 20%. Growth has been most pronounced in Southeast Asia (29.8% per year),
but is also strong in the two other main emerging regions (Eastern Europe and Latin
America, 26.3% and 24.1% respectively). The growth in tier emerging countries
can be considered more relevant since it is coming from an already relatively large
base. The other interesting finding is the relative stabilization of growth in two of the
top performing tier I emerging countries - South Africa (-2.3%) and Brazil (0.9%).
It can be concluded that hypothesis 2) can not be refuted. The participation
share of emerging countries in global clinical drug development has continued to
increase over the last four years, while the participation share of traditional countries
has been decreasing.
Participation in Very Large Clinical Trials
Over 80% of the clinical sites located in emerging countries were related to
very large trials in which the same clinical protocol was followed in more than five
countries at once. The rate of participation emerging countries was greater than that
of traditional countries (47.4%).
Most of these trials which had participation of emerging countries also had
participation of traditional countries. The most common scenario was a trial with
several dozen sites in traditional countries (especially in the U.S.) and a few (2-5)
sites in several of the emerging countries. The most notable exception to this kind of
distribution of site locations is China. It was observed that a substantial portion of
reported trials that started recently in China only had Chinese sites. This kind of
situation was also observed to a lesser extent with Eastern European countries,
especially Russia and Poland. The Latin American countries are at the other side of
37
this spectrum. A trial with sites only in Latin American countries was rarely
encountered.
As for the traditional countries, one of the most interesting findings is the
nature of Japanese trials. Japan rarely (0.1% of cases) participated in the very large
multinational trials, and its trials most often involved only Japanese sites. It was also
interesting to observe the large number of trials that involved solely the U.S. and
Canada, which sometimes had a few sites in Puerto Rico as well.
The presented data supports the notion stated in hypothesis 3), which infers
that emerging countries have a greater level of participation in large multinational
studies (with sites in more than 5 countries) than do traditional countries.
Participation in Confirmatory (Phases II and IlIl) Clinical Trials
The emerging countries have been participating in confirmatory phases (11/111)
of clinical development at a rate comparable to that of most traditional countries. The
great majority of clinical sites in tier 1 (88.1 %) and tier 2 (83.7%) emerging countries
are enrolling patients for phase II or III clinical trials (as apposed to phase IV trials).
These average proportions are similar to the ones found in traditional countries
(86.4%).
Given the described evidence, hypothesis 4) seems to be a valid statement,
as it indicates that emerging countries have a level of participation in the
confirmatory phases (phases 1/111) of clinical development at a rate that is
comparable to that of traditional countries.
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VII - Discussion
Participation of Emerging Countries in Clinical Drug Development
The participation of emerging nations in clinical development is relatively low
(13%) when compared with that of traditional countries, but still relevant for the
following reasons: 1) it amounts to a large number of clinical sites (11,038) in
absolute terms; 2) it involves many countries representing numerous different
realities and regulatory systems; 3) it is growing rapidly; and 4) it is clearly an
underestimate.
One way to put the number of clinical sites in emerging nations (11,038) in
perspective is to compare it with the sum of sites in the top four European countries
(Germany, France, U.K., and Italy), which amounts 11,061. Another way to look into
this figure is to consider the number of patients that are probably enrolled in trials in
all these emerging countries. If one uses the conservative estimate of having only
one patient recruited per site, it amounts to over 10,000 patients serving as subjects
in GCTs. This number is likely to be larger, and these research subjects are
distributed across a large number of countries with very diverse characteristics as it
refers to socioeconomic status, cultural values and health care delivery systems.
The flip side of this diversity argument is that this clinical research seems to be
taking place within a common ground that is represented in each one of these
countries, and these "islands of excellence" are serving as stepping stones for a
remarkable form of international collaboration.
Although important, this common ground present in each of the represented
emerging countries seems to be quite limited when compared to the one of
traditional countries at this point in time. The analysis of individual trials included in
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this study shows that even though emerging countries are participating in many
trials, they usually contribute with a few sites in each of the trials. More specifically,
they usually have 2-4 sites and only rarely have more than 15 sites enrolling sites for
any given trial.
This situation is not true for any of the traditional countries, which have been
shown to have the research capacity that enables them to participate with more than
50 sites on a number of occasions. The Scandinavian countries are good examples
of countries that, albeit small in terms of population, have large research capacity.
As for the larger traditional countries, like Germany, France, Canada, U.K., or the
U.S., it is hard to compare as they oftentimes have more than 100 sites enrolling for
the same trial.
These emerging countries might have a limited research capacity, but given
the impressive growth rate in GCT participation that these countries are exhibiting, it
is quite probable that their research institutions are becoming busy and diversified in
terms of the therapeutic categories they are studying. Special attention should be
paid to the tier I emerging countries that were highlighted in the 2001 OIG report
[41] covering the late 1990's (Poland, Brazil, Russia, Argentina, Czech Republic,
Mexico, and Hungary) as they had started their growth spurt in the last decade. It is
likely that the current growth is based on positive feedback obtained over the last 10
years of experience.
As for China and India, which are the fastest growing countries of the tier 1
group, such track record in participation on GCTs is very limited. India was not even
mentioned in the 2001 OG report, and China had only one site (located in Hong
Kong) in trials starting in 2002, but growing into 177 sites across the country for trials
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starting in 2005. These countries are not only growing fast, but are also quickly
expanding their capacity. For trials starting recruiting in 2005, it is easier to find
participation with more than ten sites in India and China than in the other tier 
emerging countries.
This growth rate is especially relevant because it fits relatively well with
reported projections of the pharmaceutical industry regarding allocation of sites of
GCTs into the near future [91, 98, 99]. It has been reported in informal
communications among industry representatives that the goal for trials starting today
is to place about 50% of the clinical sites in the U.S. and Canada, 25% in other
traditional countries and the other 25% in emerging nations [98]. Other industry
representatives involved in the decision making of clinical site allocation around the
globe informally project a participation of emerging economies in the order of 30 to
45% by 2010 [91, 98]. In this thesis, the presented number that refers to participation
of emerging countries in global clinical development activities is 13%, but it probably
does not capture the whole picture.
One of the main limitations of the current analysis is that it does not capture
the number of patients enrolled in each of the sites located in emerging countries.
Such information is not in the public domain, and for the currently recruiting trials, it
is oftentimes unknown by the sponsors at the time of reporting. Regardless of the
cause, this limitation is important, especially given the common understanding in the
industry that about 30% of clinical sites set up in the U.S. never recruit any patients,
while the ones which are effectively set up in emerging countries are notoriously fast
and effective recruiters [14, 16, 21, 31, 41, 99].
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Industry officials also informally indicate that the retention rate of patients in
emerging nations is greater than that of the U.S. [91, 98], therefore, patients that are
recruited in emerging countries more often result in usable data points at the end of
the study. Moreover, patients of emerging countries are less commonly taking other
medications that complicate, and sometimes impede, an independent assessment of
the effect of a given investigational drug on research subjects and their disease [14,
53, 90] 12
Another limitation of the study presented in this thesis has to do with the fact
that not all industry-sponsored trials are reported in clinicaltrials.gov. It is virtually
impossible to gauge how much is left out of clinicaltrials.gov, but industry insiders
estimate this number to be around 30% as of May 2006. This number is rapidly
decreasing and it is quite surprising to see how much detail about clinical
development activities has become available through clinicaltrials.gov just in the last
six months. As for the trials that are reported, sometimes the information is
incomplete. This is relevant for this study as the field that is most frequently
incomplete is the list of clinical sites outside the U.S.
The study limitations presented here actually point to an even greater role of
emerging economies that could be documented. However, if one limits the
discussion only to the data points that have been accounted for in this study, there is
evidence for relative stabilization of growth (if not negative average annual growth)
in traditional economies and substantial growth in the emerging ones.
In order to interpret appropriately the growth rates presented in the results
section, one has to remember that a 0% annual growth rate of the overall global
12 However, to the extent they represent drug-nalive populations, their similarity to patient populations
in the developed countries can be called into question, as can the generalization of the clinical
findings.
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clinical trials activities over the last four years was an underlying assumption used in
the generation of the results. As mentioned, this 0% overall growth rate was chosen
basically because the underlying rate is unknown and the time period (2002-2005) is
relatively short. I have performed sensitivity analysis on the model by artificially
including an annual growth rate of 5 or 10%. Not surprisingly, the inclusion of a
positive 5 or 10% overall average annual growth rate for the most part moves up the
values of all the countries by 5 or 10% correspondingly. A negative growth rate also
has the same effect on the opposite direction. Therefore, it can be concluded that
the most appropriate way to qualitatively represent the slightly negative growth rate
(-3.2%) of traditional countries presented in this study is to say that is slightly below
the overall growth rate, whatever that might be. Likewise, it can be inferred that the
share participation of tier 1 emerging countries grew at a rate that is 22.9% above
the overall growth rate, or 26.1% above the rate of traditional countries.
This pronounced growth rate of these emerging countries was not related to
increased participation in any kind of trial. The emerging countries are most often
(>80% of the cases - as opposed to 47.4% in the traditional countries) participating
in very large trials, which are the ones that recruits patients in at least five countries
at the same time 13 . The fact that these trials frequently have numerous sites in the
traditional countries as well might make their approval by ethical review boards in
emerging nations more straightforward, as it goes against the perception that the
trial location was chosen to run a clinical experiment that would not be acceptable in
traditional countries.
13 These large multinational trials are characteristically simple trials (in terms of number of clinical
endpoints or complexity of medical care provided) that have the goal of enrolling a very large number
of patients as quickly as possible.
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As for trial phase, I did not quantify how many of the phase II and III trials had
the participation of emerging economies, but this number is certainly substantial.
This participation can be inferred by the number of instances (> than 80% of the
cases) in which these emerging countries were engaged in these types of trials14
and by the overall participation of emerging countries in GCTs. This rate of
participation of emerging countries in pre-approval confirmatory (phases II and IlIl)
trials, as opposed to post-approval (phase IV) trials is very close to that of traditional
countries 15. The substantial participation of emerging countries in these phase II and
II trials strongly suggests that they are becoming significantly engaged in pre-
approval global development operations.
Clinical Drug Development in Different Regions of the Globe
Clinical development participation can also be characterized by geopolitical
regions, which share some common characteristics. Not surprisingly, the
quantification of participation by region demonstrated the clear dominance of North
America, Western Europe, and the Pacific. The other regions have a smaller
participation, but a very high growth rate.
As for North America, it comprises almost half of all sites contributing to
GCTs. If one includes the estimated number of sites (25,949) that were excluded
14 Participation of emerging countries in phase I studies was very small, but as the regulation
governing trial registration on clinicaltrials.gov is not very strong in relation to this type of trial, I
assumed that very little was actually registered and chose not to quantify the features of these trials.
Furthermore, it is not surprising that drug innovators chose to keep these phase I trials close to the
sponsor's headquarters within the traditional countries. The main issues with bringing phase I trials to
emerging nations is the fear of losing key intellectual property, the relatively small sizes and costs of
these trials, and the heightened sensitivity around drug testing with financial compensation in normal
subjects living in impoverished locations.
"5 A good number of the post-approval studies that are specific to each country were clearly not
captured in this database, either because of my exclusion criteria or because some of them do not
need to be in the U.S.-centric clinicaltrials.gov database.
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because they were only in domestic (U.S. only) trials, the estimated participation
share of this region goes to 62%. The growth rate of this region was coincidentally
the same as the assumed overall growth rate (0.0%), but I can not ascertain that this
is true because I do not know how the proportion between domestic and GCTs with
U.S. participation changed over the last years, as these trials were excluded from
the database. Even though the U.S. story is not clear, the negative (-9.5%) average
annual growth observed in Canada is of interest. This country is still the preferred
destination for clinical sites outside the U.S., but now seems to be losing some
ground.
Likewise, Western Europe has a very large number of clinical trials, especially
considering that it also hosts numerous academic and/or public funded studies that
were not included in this database. Notwithstanding, the negative (-7.9%) average
annual growth rate of this region is substantial. Many countries presented significant
(<-10%) negative growth (Germany, U.K., Italy, Norway, Austria, and Switzerland),
while some actually were in the positive or neutral space (France, Spain, Belgium,
Netherlands, Sweden, Denmark, Finland, Ireland and Portugal). It seems clear that
the allocation of clinical trial activities is changing substantially within Europe.
The story for the arbitrarily defined (includes Greece and Turkey) Eastern
Europe is also quite extraordinary. This region has been experiencing substantial
growth (26.3%), and is the one that presents the largest participation share in GCTs
(8.0%) when compared to that of other mostly emerging regions like Latin America
(3.7%) and Southeast Asia (3.2%). The combination of this growth rate with the fact
that these countries are already coming from a relatively large base makes them
increasingly important.
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In terms of performance, the situation of Latin America is intermediary
between Eastern Europe and Southeast Asia. The Latin American countries already
have a substantial base, especially considering that their number of players (6
countries) is less than half of the one of Eastern Europe (13 countries) and less than
Southeast Asia (8 countries). The growth of Latin America is still substantial (24.1%),
with the notable exception of their top performer (Brazil), which is basically keeping
up with the overall annual growth rate (0.9%).
Southeast Asia is the region that is experiencing the highest growth rate
(29.8%). It comprises many countries with huge populations and reportedly the
potential to take on the world of clinical development [53, 90]. Even though this
phenomenon has not happened yet, one might be able to see it on the horizon.
China and India have grown from basically nothing to occupy respectable positions
in just four years, with average annual growth rates of 40.1% for India and 61.9% for
China. In any case, the quantification of annual growth rate is problematic when one
starts from a very small base. I dealt with this problem in this study with the
application of a mathematical formula that is designed to handle this situation (arc
elasticity - arithmetic mean).
Most of the Pacific countries, on the contrary, are large players (Japan and
Australia). Even though these countries seemed to be less engaged in GCTs than
countries in Western Europe or in emerging markets, such relationship did not
change substantially in the last few years. The exception to this profile for wealthy
Pacific countries is New Zealand, which has a small participation in GCTs (0.2%), is
growing rapidly (27.9%), and is most commonly involved in large multinational trials
(86.4% of its sites).
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The only country in the African continent that made it to the top 50 list was
South Africa. This country is presenting moderate negative growth (-2.3%), which
was not frequently seen for emerging countries. Notwithstanding, South Africa is a
top performing tier I emerging country, which is most heavily involved in large
multinational trials (89.8% of the cases).
In the Middle East, Israel is the only representative. This country has
experienced significant positive growth (12.4%) and has a participation (317 trials)
that puts it close to the tier 1 countries.
Since I did not capture the identities of the countries for which sites were
represented in aggregate ("others" bin), I can only limit myself to say that the
individual participation of countries outside the top 50 list was very small (less than
0.1% each).The choice of studying only the top 50 countries in detail was shown to
be appropriate as it has captured the performance of the major players while
identifying trends in almost all the small emerging economies that had significant
participation.
Globalization of Clinical Drug Development and its Implications
The role of emerging economies in global clinical development is already
substantial. Considering that there is evidence that this participation is going to grow
even more in the near future, the major stakeholders (governments, companies,
regulatory agencies, and health care delivery systems) need to adjust to this new
reality accordingly.
At the end of the day, growth rates in emerging countries will only be
sustained if these countries continue to invest in education (population and health
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care professionals), health care infrastructure, intellectual property protection,
effective and expeditious systems for ethical review of human research,
transportation and communication systems, and ultimately develop a substantial
market for pharmaceutical products. If all those things do not occur concomitantly,
the long-term viability of this drug development model will probably be quite limited
and it will continue to be under the considerable risk of a major set-back based on
possible incidents involving lax subject protection of vulnerable populations.
On the other hand, if these countries move in the right direction in terms of
patient protection and continue to strengthen their research capacity, it is easy to
see how they can continue to grow at a rapid pace to become prominent players in
global clinical development in the next twenty years. The current paradigm of having
a relatively small number of centers of academic excellence located in these
emerging nations participating in GCTs might gradually change. These countries
may continue to add land to their "islands of excellence", turning the common ground
that they have with the developed world into the rule, rather than exception. This
transition would likely expand the global clinical research capacity to an
unprecedented scale.
One of the ways that this mentioned transition might change medical product
development has to do with neglected diseases that are characteristic of the
developing world. A substantial improvement in health care delivery systems, and
corresponding research capacity, in emerging nations would enable them to
effectively deal with their own diseases. One important impediment today to the R&D
of drugs targeted at neglected diseases of the developing world is the insufficient
number of local trained health care professionals with research experience, and the
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inappropriate health care infrastructure to run the clinical trials of the drugs that are
getting into the pipeline more recently [3, 16, 63].
This pipeline has been created with the support of public-private partnerships
such as the Gates Foundation, which now has increasing collaboration with large
pharmaceutical companies. This interest of drug developers in neglected diseases is
tightly coupled with the mentioned gradual involvement of pharmaceutical
companies in emerging markets through the adoption of a global clinical
development paradigm for diseases common to the developed and developing
world.
While the initial driver for global trials on the types of diseases that are
common to all countries was the need for more cost-effective access to research
subjects, companies have been also increasingly seeking concomitant global
registration so that no product lifetime for truly global products is wasted in these fast
growing emerging markets. This global/local registration effort is driven by market
forces, but ends up changing the way that drug developers interact with regulatory
agencies, which are not necessarily set up to deal with global clinical drug
development activities.
Even though harmonization of clinical guidelines (ICH) was a very important
positive change, regulatory agencies - especially the U.S. FDA - now have to deal
with information coming from a much greater number of clinical sites and countries
that they are not familiar with [99]. Inspections from the FDA or EMEA on these
international sites can only do part of the job, and it is clear that in the long run
strong collaboration among regulatory agencies of all these involved countries will
be needed. The Chinese FDA (sFDA) has taken a step in this direction, and has
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begun to do its own inspections, gradually building a list of clinical sites that are
considered suitable to recruit patients for GCTs. This Chinese agency seems to be
very interested in becoming harmonized with the work performed at the U.S. FDA,
attested by the choice of its official name (sFDA).
It is clear that in this globalized scenario countries, companies, regulatory
agencies, clinical research institutions, health care providers and patients are
moving closer together. The interesting piece is that they are moving closer in a
world that is rapidly expanding with possibly beneficial outcomes to all these
stakeholders.
In this new world patients of emerging nations are vulnerable, as there is still
so much income inequality, inadequate access to health care, and ineffective
education. On the other hand, if patient abuse does not occur at this initial stage and
these emerging countries continue to move towards full blown development, the
same patients will greatly benefit. They will have better drugs tailored to their
biological and cultural condition and local health care systems that can deliver state-
of-the-art medical care, just like their counterparts in the developed world.
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VIII - Conclusions and Future Research
The key findings of this study are:
1) The top 50 countries that are most actively taking part in global clinical trials
of investigational drugs either have high income per capita (more than
US$10,00016 in 2005) or are "emerging markets" tracked by The Economist® .
2) The participation share of emerging countries in global clinical drug
development has continued to increase over the last four years, while the
participation share of traditional countries has been decreasing.
3) Emerging countries have a greater level of participation in large multinational
studies (with sites in more than five countries) than do traditional countries.
4) Emerging countries have a level of participation in the confirmatory phases
(phases 11/111) of clinical development at a rate that is comparable to that of
traditional countries.
It is clear that the globalization of clinical drug development is a highly
complex process that has the potential of changing standards of health care delivery
around the globe. This thesis provides a quantitative assessment of this
phenomenon and describes some of its key characteristics, including the recent
evolution of the participation of important players in this process, which are the
emerging countries. I have also described the types of trials that have been
conducted in these countries, and discussed some of the major trends in the field of
global clinical drug development.
This presented work would not be possible without the recent disclosure of
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16 CIA World FactBook 2005.
information on clinical development activities at the clinicaltrials.gov website. It is
clear that the kind of approach used to analyze drug development information in this
study can objectively address many issues of importance to policy makers of all
involved countries, managers in the pharmaceutical industry, health care providers,
and their patients.
This study will be expanded in several ways to address some key questions
that remained mostly unanswered in the presented thesis. One key question that is
not yet adequately addressed is the growth rate of the U.S., which is by far the major
player in clinical development today. The inclusion of U.S. clinical trials in my
database in the near future will enable me to answer this question. One can actually
take a step further to look at the evolution of clinical site allocation within the U.S.
over the last years in order to address the raised question that trials are moving from
northern states towards the south [99].
The inclusion of U.S. clinical trials will also enable me to address several
other questions, including the overall proportion of phase II and III trials going to
emerging countries and how that is changing with time. I can also determine how the
allocation of trials of different therapeutic categories has been changing over the last
years. Furthermore, I might be able to correlate year-to-year growth rate of key
countries in clinical development with their public policies and major initiatives by the
private sector.
My ultimate goal is to create a live document that is updated as the
clinicaltrials.gov registry is updated daily. The other goal is to establish relationships
with drug developers to see if data that is not published in the clinicaltrials.gov can
be included in the database of clinical development to be analyzed in aggregate. It is
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clear that a continued systematic and objective analysis of global clinical
development activities moving forward is going to be an important contribution to all
stakeholders involved in the drug development process.
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